Charles Schwab Investment Management Inc. Raises Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDFree Report) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,288,653 shares of the biotechnology company’s stock after purchasing an additional 57,859 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.83% of Ironwood Pharmaceuticals worth $14,742,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Walleye Capital LLC purchased a new stake in Ironwood Pharmaceuticals in the third quarter worth approximately $1,608,000. Illinois Municipal Retirement Fund purchased a new stake in Ironwood Pharmaceuticals in the third quarter worth approximately $743,000. Jacobs Levy Equity Management Inc. purchased a new stake in Ironwood Pharmaceuticals in the third quarter worth approximately $22,903,000. Vanguard Group Inc. boosted its stake in Ironwood Pharmaceuticals by 0.3% in the third quarter. Vanguard Group Inc. now owns 14,895,700 shares of the biotechnology company’s stock worth $143,446,000 after buying an additional 49,160 shares in the last quarter. Finally, Quantbot Technologies LP boosted its stake in Ironwood Pharmaceuticals by 95.8% in the third quarter. Quantbot Technologies LP now owns 69,500 shares of the biotechnology company’s stock worth $669,000 after buying an additional 34,000 shares in the last quarter.

Analyst Ratings Changes

Several analysts have issued reports on IRWD shares. Piper Sandler upped their target price on Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Wells Fargo & Company lowered their price objective on Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, March 1st. Craig Hallum lowered their price objective on Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Finally, StockNews.com downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $18.40.

Read Our Latest Research Report on Ironwood Pharmaceuticals

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Jon R. Duane bought 6,920 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average price of $8.70 per share, for a total transaction of $60,204.00. Following the completion of the acquisition, the director now directly owns 121,028 shares in the company, valued at $1,052,943.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Sravan Kumar Emany purchased 10,684 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, March 4th. The shares were bought at an average cost of $9.38 per share, with a total value of $100,215.92. Following the completion of the purchase, the chief financial officer now directly owns 301,733 shares in the company, valued at $2,830,255.54. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jon R. Duane purchased 6,920 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $8.70 per share, for a total transaction of $60,204.00. Following the completion of the purchase, the director now owns 121,028 shares of the company’s stock, valued at $1,052,943.60. The disclosure for this purchase can be found here. 12.90% of the stock is owned by corporate insiders.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock opened at $5.95 on Tuesday. The company has a market capitalization of $931.35 million, a P/E ratio of -0.88 and a beta of 0.57. The stock has a 50 day moving average price of $7.76 and a two-hundred day moving average price of $10.35. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Free Report) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.20). The business had revenue of $74.90 million for the quarter, compared to the consensus estimate of $105.75 million. Ironwood Pharmaceuticals had a negative net margin of 254.41% and a negative return on equity of 28.45%. Ironwood Pharmaceuticals’s revenue was down 28.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.25 EPS. As a group, equities analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.56 earnings per share for the current year.

About Ironwood Pharmaceuticals

(Free Report)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

Read More

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.